Literature DB >> 28335839

Apolipoprotein L1 Variants and Blood Pressure Traits in African Americans.

Girish N Nadkarni1, Geneviève Galarneau1, Stephen B Ellis1, Rajiv Nadukuru1, Jinglan Zhang1, Stuart A Scott1, Claudia Schurmann1, Rongling Li2, Laura J Rasmussen-Torvik3, Abel N Kho3, M Geoffrey Hayes4, Jennifer A Pacheco3, Teri A Manolio2, Rex L Chisholm3, Dan M Roden5, Joshua C Denny5, Eimear E Kenny1, Erwin P Bottinger6.   

Abstract

BACKGROUND: African Americans (AA) are disproportionately affected by hypertension-related health disparities. Apolipoprotein L1 (APOL1) risk variants are associated with kidney disease in hypertensive AAs.
OBJECTIVES: This study assessed the APOL1 risk alleles' association with blood pressure traits in AAs.
METHODS: The discovery cohort included 5,204 AA participants from Mount Sinai's BioMe biobank. Replication cohorts included additional BioMe (n = 1,623), Vanderbilt BioVU (n = 1,809), and Northwestern NUgene (n = 567) AA biobank participants. Single nucleotide polymorphisms determining APOL1 G1 and G2 risk alleles were genotyped in BioMe and imputed in BioVU/NUgene participants. APOL1 risk alleles' association with blood pressure-related traits was tested in the discovery cohort, a meta-analysis of replication cohorts, and a combined meta-analysis under recessive and additive models after adjusting for age, sex, body mass index, and estimated glomerular filtration rate.
RESULTS: There were 14% to 16% of APOL1 variant allele homozygotes (2 copies of G1/G2) across cohorts. APOL1 risk alleles were associated under an additive model with systolic blood pressure (SBP) and age at diagnosis of hypertension, which was 2 to 5 years younger in the APOL1 variant allele homozygotes (Cox proportional hazards analysis, p value for combined meta-analysis [pcom] = 1.9 × 10-5). APOL1 risk alleles were associated with overall SBP (pcom = 7.0 × 10-8) and diastolic blood pressure (pcom = 2.8 × 10-4). After adjustment for all covariates, those in the 20- to 29-year age range showed an increase in SBP of 0.94 ± 0.44 mm Hg (pcom = 0.01) per risk variant copy. APOL1-associated estimated glomerular filtration rate decline was observed starting a decade later in life in the 30- to 39-year age range.
CONCLUSIONS: APOL1 risk alleles are associated with higher SBP and earlier hypertension diagnoses in young AAs; this relationship appears to follow an additive model.
Copyright © 2017 American College of Cardiology Foundation. All rights reserved.

Entities:  

Keywords:  APOL1; allele; estimated glomerular filtration rate; genetic association studies; kidney disease

Mesh:

Substances:

Year:  2017        PMID: 28335839      PMCID: PMC5479565          DOI: 10.1016/j.jacc.2017.01.040

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  37 in total

1.  A linear complexity phasing method for thousands of genomes.

Authors:  Olivier Delaneau; Jonathan Marchini; Jean-François Zagury
Journal:  Nat Methods       Date:  2011-12-04       Impact factor: 28.547

2.  APOL1 variants and kidney disease in people of recent African ancestry.

Authors:  Giulio Genovese; David J Friedman; Martin R Pollak
Journal:  Nat Rev Nephrol       Date:  2013-02-26       Impact factor: 28.314

3.  End-stage renal disease in African Americans with lupus nephritis is associated with APOL1.

Authors:  Barry I Freedman; Carl D Langefeld; Kelly K Andringa; Jennifer A Croker; Adrienne H Williams; Neva E Garner; Daniel J Birmingham; Lee A Hebert; Pamela J Hicks; Mark S Segal; Jeffrey C Edberg; Elizabeth E Brown; Graciela S Alarcón; Karen H Costenbader; Mary E Comeau; Lindsey A Criswell; John B Harley; Judith A James; Diane L Kamen; S Sam Lim; Joan T Merrill; Kathy L Sivils; Timothy B Niewold; Neha M Patel; Michelle Petri; Rosalind Ramsey-Goldman; John D Reveille; Jane E Salmon; Betty P Tsao; Keisha L Gibson; Joyce R Byers; Anna K Vinnikova; Janice P Lea; Bruce A Julian; Robert P Kimberly
Journal:  Arthritis Rheumatol       Date:  2014-02       Impact factor: 10.995

4.  MYH9 and APOL1 are both associated with sickle cell disease nephropathy.

Authors:  Allison E Ashley-Koch; Emmanuel C Okocha; Melanie E Garrett; Karen Soldano; Laura M De Castro; Jude C Jonassaint; Eugene P Orringer; James R Eckman; Marilyn J Telen
Journal:  Br J Haematol       Date:  2011-09-13       Impact factor: 6.998

5.  APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy.

Authors:  Jeffrey B Kopp; George W Nelson; Karmini Sampath; Randall C Johnson; Giulio Genovese; Ping An; David Friedman; William Briggs; Richard Dart; Stephen Korbet; Michele H Mokrzycki; Paul L Kimmel; Sophie Limou; Tejinder S Ahuja; Jeffrey S Berns; Justyna Fryc; Eric E Simon; Michael C Smith; Howard Trachtman; Donna M Michel; Jeffrey R Schelling; David Vlahov; Martin Pollak; Cheryl A Winkler
Journal:  J Am Soc Nephrol       Date:  2011-10-13       Impact factor: 10.121

6.  Evolution of the primate trypanolytic factor APOL1.

Authors:  Russell Thomson; Giulio Genovese; Chelsea Canon; Daniella Kovacsics; Matthew K Higgins; Mark Carrington; Cheryl A Winkler; Jeffrey Kopp; Charles Rotimi; Adebowale Adeyemo; Ayo Doumatey; George Ayodo; Seth L Alper; Martin R Pollak; David J Friedman; Jayne Raper
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-07       Impact factor: 11.205

Review 7.  Hypertension and socioeconomic status.

Authors:  Itamar Grotto; Michael Huerta; Yehonatan Sharabi
Journal:  Curr Opin Cardiol       Date:  2008-07       Impact factor: 2.161

8.  Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene.

Authors:  Shay Tzur; Saharon Rosset; Revital Shemer; Guennady Yudkovsky; Sara Selig; Ayele Tarekegn; Endashaw Bekele; Neil Bradman; Walter G Wasser; Doron M Behar; Karl Skorecki
Journal:  Hum Genet       Date:  2010-07-16       Impact factor: 4.132

9.  Direct Estimates of the Genomic Contributions to Blood Pressure Heritability within a Population-Based Cohort (ARIC).

Authors:  Elias Salfati; Alanna C Morrison; Eric Boerwinkle; Aravinda Chakravarti
Journal:  PLoS One       Date:  2015-07-10       Impact factor: 3.240

10.  Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans.

Authors:  Michael S Lipkowitz; Barry I Freedman; Carl D Langefeld; Mary E Comeau; Donald W Bowden; W H Linda Kao; Brad C Astor; Erwin P Bottinger; Sudha K Iyengar; Paul E Klotman; Richard G Freedman; Weijia Zhang; Rulan S Parekh; Michael J Choi; George W Nelson; Cheryl A Winkler; Jeffrey B Kopp
Journal:  Kidney Int       Date:  2012-07-25       Impact factor: 10.612

View more
  21 in total

Review 1.  One Actor, Many Roles: Histopathologies Associated With APOL1 Genetic Variants.

Authors:  Jeffrey B Kopp; Avi Z Rosenberg
Journal:  Adv Anat Pathol       Date:  2019-05       Impact factor: 3.875

Review 2.  The Impact of APOL1 on Chronic Kidney Disease and Hypertension.

Authors:  Todd W Robinson; Barry I Freedman
Journal:  Adv Chronic Kidney Dis       Date:  2019-03       Impact factor: 3.620

3.  Worldwide Frequencies of APOL1 Renal Risk Variants.

Authors:  Girish N Nadkarni; Christopher R Gignoux; Elena P Sorokin; Michelle Daya; Rayees Rahman; Kathleen C Barnes; Christina L Wassel; Eimear E Kenny
Journal:  N Engl J Med       Date:  2018-12-27       Impact factor: 91.245

4.  LRG1 Promotes Diabetic Kidney Disease Progression by Enhancing TGF-β-Induced Angiogenesis.

Authors:  Quan Hong; Lu Zhang; Jia Fu; Divya A Verghese; Kinsuk Chauhan; Girish N Nadkarni; Zhengzhe Li; Wenjun Ju; Matthias Kretzler; Guang-Yan Cai; Xiang-Mei Chen; Vivette D D'Agati; Steven G Coca; Detlef Schlondorff; John C He; Kyung Lee
Journal:  J Am Soc Nephrol       Date:  2019-03-11       Impact factor: 10.121

5.  Plasma biomarkers are associated with renal outcomes in individuals with APOL1 risk variants.

Authors:  Girish N Nadkarni; Kinsuk Chauhan; Divya A Verghese; Chirag R Parikh; Ron Do; Carol R Horowitz; Erwin P Bottinger; Steven G Coca
Journal:  Kidney Int       Date:  2018-04-25       Impact factor: 10.612

Review 6.  APOL1 and kidney cell function.

Authors:  Vinod Kumar; Pravin C Singhal
Journal:  Am J Physiol Renal Physiol       Date:  2019-06-26

Review 7.  Apolipoprotein L1 nephropathies: 2017 in review.

Authors:  Jeffrey B Kopp; Hila Roshanravan; Koji Okamoto
Journal:  Curr Opin Nephrol Hypertens       Date:  2018-05       Impact factor: 2.894

Review 8.  APOL1 polymorphisms and kidney disease: loss-of-function or gain-of-function?

Authors:  Leslie A Bruggeman; John F O'Toole; John R Sedor
Journal:  Am J Physiol Renal Physiol       Date:  2018-10-17

9.  Plasma endostatin predicts kidney outcomes in patients with type 2 diabetes.

Authors:  Kinsuk Chauhan; Divya Anna Verghese; Veena Rao; Lili Chan; Chirag R Parikh; Steven G Coca; Girish N Nadkarni
Journal:  Kidney Int       Date:  2018-12-24       Impact factor: 10.612

10.  Phenome-wide association analysis suggests the APOL1 linked disease spectrum primarily drives kidney-specific pathways.

Authors:  Archna Bajaj; Andrea Ihegword; Chengxiang Qiu; Aeron M Small; Wei-Qi Wei; Lisa Bastarache; QiPing Feng; Rachel L Kember; Marjorie Risman; Roy D Bloom; David L Birtwell; Heather Williams; Christian M Shaffer; Jinbo Chen; Regeneron Genetics Center; Joshua C Denny; Daniel J Rader; C Michael Stein; Scott M Damrauer; Katalin Susztak
Journal:  Kidney Int       Date:  2020-02-17       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.